These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34839327)

  • 41. Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.
    Vatier C; Vantyghem MC; Storey C; Jéru I; Christin-Maitre S; Fève B; Lascols O; Beltrand J; Carel JC; Vigouroux C; Bismuth E
    Curr Med Res Opin; 2019 Mar; 35(3):543-552. PubMed ID: 30296183
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline.
    Xu J; Ashjian E
    J Pharm Pract; 2023 Jun; 36(3):650-661. PubMed ID: 34720008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complications of lipodystrophy syndromes.
    Akinci G; Celik M; Akinci B
    Presse Med; 2021 Nov; 50(3):104085. PubMed ID: 34728268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical presentation and treatment of primary lipodystrophies].
    Cortés V; Santos JL
    Rev Med Chil; 2019 Nov; 147(11):1449-1457. PubMed ID: 32186606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
    Maggi P; Di Biagio A; Rusconi S; Cicalini S; D'Abbraccio M; d'Ettorre G; Martinelli C; Nunnari G; Sighinolfi L; Spagnuolo V; Squillace N
    BMC Infect Dis; 2017 Aug; 17(1):551. PubMed ID: 28793863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy.
    Lightbourne M; Startzell M; Bruce KD; Brite B; Muniyappa R; Skarulis M; Shamburek R; Gharib AM; Ouwerkerk R; Walter M; Eckel RH; Brown RJ
    J Clin Lipidol; 2022; 16(6):850-862. PubMed ID: 36195542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
    Alexander VJ; Xia S; Hurh E; Hughes SG; O'Dea L; Geary RS; Witztum JL; Tsimikas S
    Eur Heart J; 2019 Sep; 40(33):2785-2796. PubMed ID: 31329855
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
    Ward NC; Chan DC; Watts GF
    BioDrugs; 2022 Mar; 36(2):121-135. PubMed ID: 35286660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G; Akinci B
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.
    Lambadiari V; Kountouri A; Maratou E; Liatis S; Dimitriadis GD; Karpe F
    Front Endocrinol (Lausanne); 2021; 12():684182. PubMed ID: 34168618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia.
    Surma S; Romańczyk M; Filipiak KJ
    Cardiol J; 2023; 30(1):131-142. PubMed ID: 33470417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
    Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
    J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities.
    Vantyghem MC; Pigny P; Maurage CA; Rouaix-Emery N; Stojkovic T; Cuisset JM; Millaire A; Lascols O; Vermersch P; Wemeau JL; Capeau J; Vigouroux C
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5337-46. PubMed ID: 15531479
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People.
    Özen S; Akıncı B; Oral EA
    J Clin Res Pediatr Endocrinol; 2020 Mar; 12(1):17-28. PubMed ID: 31434462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?
    Florentin M; Kostapanos MS; Anagnostis P; Liamis G
    Expert Opin Pharmacother; 2020 Jan; 21(1):107-120. PubMed ID: 31738617
    [No Abstract]   [Full Text] [Related]  

  • 58. Serum adiponectin and leptin levels in patients with lipodystrophies.
    Haque WA; Shimomura I; Matsuzawa Y; Garg A
    J Clin Endocrinol Metab; 2002 May; 87(5):2395. PubMed ID: 11994394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lipodystrophies: adipose tissue disorders with severe metabolic implications.
    Cortés VA; Fernández-Galilea M
    J Physiol Biochem; 2015 Sep; 71(3):471-8. PubMed ID: 25833179
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lipodystrophies.
    Garg A
    Am J Med; 2000 Feb; 108(2):143-52. PubMed ID: 11126308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.